AN2 Therapeutics Inc
ANTX1.141USD
+0.001+0.05%
收盘 11/05, 16:00（美东）报价延迟15分钟
31.23M总市值
亏损市盈率 TTM
关于 AN2 Therapeutics Inc 公司
AN2 Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司致力于开发罕见、慢性和严重传染病的治疗方法，这些疾病具有很高的未满足需求。其初始候选药物是 epetraborole，这是一种潜在的每日一次口服治疗药物，具有新颖的作用机制，适用于非结核分枝杆菌 (NTM) 肺病患者，这是一种由被称为分枝杆菌的细菌引起的罕见、慢性和进行性传染病，会导致不可逆的肺损伤并可能致命。Epetraborole 旨在通过抑制细菌蛋白质合成中必不可少的通用步骤来产生广谱抗分枝杆菌活性。Epetraborole 是一种在研的含硼、口服生物可利用的小分子细菌亮氨酰-tRNA 合成酶 (LeuRS) 抑制剂，该酶催化亮氨酸与转移 RNA (tRNA) 分子的连接，这是蛋白质合成中必不可少的步骤。
AN2 Therapeutics Inc简介
公司代码ANTX
公司名称AN2 Therapeutics Inc
上市日期Mar 25, 2022
CEOMr. Eric Easom
员工数量22
证券类型Ordinary Share
年结日Mar 25
公司地址1800 El Camino Real, Suite D
城市MENLO PARK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94027
电话16503319090
网址https://www.an2therapeutics.com/
公司代码ANTX
上市日期Mar 25, 2022
CEOMr. Eric Easom
AN2 Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.30M
+0.78%
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
74.79K
+204.74%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
63.75K
+19.42%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
40.92K
+33.93%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
27.34K
-83.95%
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Lead Independent Director
Lead Independent Director
8.61K
--
Ms. Stephanie Wong
Ms. Stephanie Wong
Independent Director
Independent Director
--
--
Dr. Melvin K. Spigelman, M.D.
Dr. Melvin K. Spigelman, M.D.
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
Ms. Lucy O. Day
Ms. Lucy O. Day
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Eric Easom
Mr. Eric Easom
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.30M
+0.78%
Dr. Sanjay Chanda, Ph.D.
Dr. Sanjay Chanda, Ph.D.
Chief Development Officer
Chief Development Officer
74.79K
+204.74%
Dr. Gilbert Lynn Marks, M.D.
Dr. Gilbert Lynn Marks, M.D.
Independent Director
Independent Director
63.75K
+19.42%
Mr. Kabeer Aziz
Mr. Kabeer Aziz
Independent Director
Independent Director
40.92K
+33.93%
Mr. Joshua M. (Josh) Eizen, J.D.
Mr. Joshua M. (Josh) Eizen, J.D.
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
Chief Operating Officer, Chief Legal Officer, Corporate Secretary
27.34K
-83.95%
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Lead Independent Director
Lead Independent Director
8.61K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
Coastlands Capital LP
10.30%
Adjuvant Global Health Technology Fund LP
7.30%
Almitas Capital LLC
5.23%
Easom (Eric)
4.75%
Readnour (Robin Shane)
4.55%
其他
67.87%
持股股东
持股股东
占比
Coastlands Capital LP
10.30%
Adjuvant Global Health Technology Fund LP
7.30%
Almitas Capital LLC
5.23%
Easom (Eric)
4.75%
Readnour (Robin Shane)
4.55%
其他
67.87%
股东类型
持股股东
占比
Hedge Fund
15.84%
Investment Advisor
14.81%
Corporation
13.31%
Individual Investor
12.54%
Research Firm
3.61%
Investment Advisor/Hedge Fund
3.54%
Bank and Trust
1.68%
Venture Capital
0.10%
其他
34.56%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
118
10.82M
39.58%
-15.53M
2025Q2
134
18.13M
60.10%
-14.59M
2025Q1
160
20.65M
68.51%
-15.04M
2024Q4
163
20.53M
68.71%
-11.12M
2024Q3
157
21.17M
72.85%
-11.75M
2024Q2
153
27.10M
92.74%
-285.84K
2024Q1
153
26.60M
91.20%
-1.58M
2023Q4
131
28.26M
99.67%
+1.32M
2023Q3
113
27.74M
102.63%
+8.68M
2023Q2
100
19.53M
93.63%
+4.46M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Coastlands Capital LP
2.82M
10.3%
+2.82M
--
May 28, 2025
Adjuvant Global Health Technology Fund LP
2.00M
7.3%
-377.54K
-15.91%
Dec 31, 2024
Almitas Capital LLC
1.43M
5.23%
+115.21K
+8.77%
Jun 30, 2025
Easom (Eric)
1.30M
4.75%
+10.00K
+0.78%
Jun 02, 2025
Readnour (Robin Shane)
1.24M
4.55%
+335.00K
+36.86%
Mar 24, 2025
The Vanguard Group, Inc.
1.04M
3.79%
--
--
Jun 30, 2025
Brii Biosciences Ltd,.
927.20K
3.39%
+927.20K
--
Dec 31, 2024
Pfizer Inc
715.29K
2.62%
--
--
Jun 30, 2025
Peapod Lane Capital LLC
582.77K
2.13%
+1.92K
+0.33%
Jun 30, 2025
Zakrzewski (Joseph S)
551.42K
2.02%
+10.52K
+1.95%
Apr 10, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Morningstar Small-Cap ETF
0%
Avantis US Equity ETF
0%
iShares Micro-Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
Avantis US Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
